KR20140146086A - 티로신 키나제 억제제 조합물 및 그의 용도 - Google Patents

티로신 키나제 억제제 조합물 및 그의 용도 Download PDF

Info

Publication number
KR20140146086A
KR20140146086A KR1020147027542A KR20147027542A KR20140146086A KR 20140146086 A KR20140146086 A KR 20140146086A KR 1020147027542 A KR1020147027542 A KR 1020147027542A KR 20147027542 A KR20147027542 A KR 20147027542A KR 20140146086 A KR20140146086 A KR 20140146086A
Authority
KR
South Korea
Prior art keywords
tyrosine kinase
combination
met
fgfr
kinase activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020147027542A
Other languages
English (en)
Korean (ko)
Inventor
랄프 티트
알랜 버클러
프레드 하빈스키
스네하 상하비
더글라스 제프리
크리스토퍼 윌슨
Original Assignee
노파르티스 아게
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 노파르티스 아게 filed Critical 노파르티스 아게
Publication of KR20140146086A publication Critical patent/KR20140146086A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020147027542A 2012-04-03 2013-04-01 티로신 키나제 억제제 조합물 및 그의 용도 Withdrawn KR20140146086A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261619502P 2012-04-03 2012-04-03
US61/619,502 2012-04-03
PCT/US2013/034759 WO2013151913A1 (en) 2012-04-03 2013-04-01 Tyrosine kinase inhibitor combinations and their use

Publications (1)

Publication Number Publication Date
KR20140146086A true KR20140146086A (ko) 2014-12-24

Family

ID=48184451

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020147027542A Withdrawn KR20140146086A (ko) 2012-04-03 2013-04-01 티로신 키나제 억제제 조합물 및 그의 용도

Country Status (11)

Country Link
US (1) US20150051210A1 (https=)
EP (1) EP2833917A1 (https=)
JP (1) JP2015512447A (https=)
KR (1) KR20140146086A (https=)
CN (1) CN104244982A (https=)
AU (1) AU2013243737B2 (https=)
CA (1) CA2866321A1 (https=)
IN (1) IN2014DN07410A (https=)
MX (1) MX2014011987A (https=)
RU (1) RU2014143213A (https=)
WO (1) WO2013151913A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6752715B2 (ja) 2014-03-26 2020-09-09 アステックス、セラピューティックス、リミテッドＡｓｔｅｘ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 組合せ
ES2831416T3 (es) * 2014-07-31 2021-06-08 Novartis Ag Terapia de combinación de un inhibidor de MET y un inhibidor de EGFR
ES2887148T3 (es) 2015-03-25 2021-12-21 Nat Cancer Ct Agente terapéutico contra el cáncer de vías biliares
US12414945B2 (en) 2015-12-17 2025-09-16 Eisai R&D Management Co., Ltd. Therapeutic agent for breast cancer

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0512324D0 (en) 2005-06-16 2005-07-27 Novartis Ag Organic compounds
DE102005038537A1 (de) 2005-08-16 2007-02-22 Merck Patent Gmbh 1-Acyldihydropyrazolderivate
HUE030390T2 (en) 2005-12-21 2017-05-29 Janssen Pharmaceutica Nv Triazolopyridazines as tyrosine kinase modulators
NL2000613C2 (nl) 2006-05-11 2007-11-20 Pfizer Prod Inc Triazoolpyrazinederivaten.
PE20080403A1 (es) 2006-07-14 2008-04-25 Amgen Inc Derivados heterociclicos fusionados y metodos de uso
AU2007309149C1 (en) 2006-10-23 2013-04-04 Sgx Pharmaceuticals, Inc. Bicyclic triazoles as protein kinase modulators
ME02372B (me) * 2006-11-22 2016-06-20 Incyte Holdings Corp Imidazotriazini i imidazopiramidini kao inhibitori kinaze
JP4994044B2 (ja) * 2007-01-05 2012-08-08 シェブロンジャパン株式会社 潤滑油組成物
CA2683559C (en) * 2007-04-13 2019-09-24 Dana Farber Cancer Institute, Inc. Methods for treating cancer resistant to erbb therapeutics
CA2720888A1 (en) * 2008-04-29 2009-11-05 Novartis Ag Methods of monitoring the modulation of the kinase activity of fibroblast growth factor receptor and uses of said methods
EP2288383A1 (en) * 2008-05-14 2011-03-02 Amgen, Inc Combinations vegf(r) inhibitors and hepatocyte growth factor (c-met) inhibitors for the treatment of cancer
JP5781510B2 (ja) 2009-08-12 2015-09-24 ノバルティス アーゲー ヘテロ環式ヒドラゾン化合物および癌および炎症の処置のためのそれらの使用
EP2621483A1 (en) * 2010-09-27 2013-08-07 Exelixis, Inc. Dual inhibitors of met and vegf for the treatment of castration resistant prostate cancer and osteoblastic bone metastases

Also Published As

Publication number Publication date
MX2014011987A (es) 2014-11-10
JP2015512447A (ja) 2015-04-27
RU2014143213A (ru) 2016-05-27
CN104244982A (zh) 2014-12-24
IN2014DN07410A (https=) 2015-04-24
US20150051210A1 (en) 2015-02-19
AU2013243737A1 (en) 2014-09-25
EP2833917A1 (en) 2015-02-11
CA2866321A1 (en) 2013-10-10
WO2013151913A1 (en) 2013-10-10
AU2013243737B2 (en) 2016-06-30

Similar Documents

Publication Publication Date Title
US20190134033A1 (en) Pharmaceutical combinations
TW202045171A (zh) 包含tno155和瑞博西尼之藥物組合
EP2834246B1 (en) Combination products with tyrosine kinase inhibitors and their use
MXPA06008157A (es) Tratamiento de gliomas malignos con inhibidores de factor de crecimiento transformante-beta.
JP2023504046A (ja) ジアリール大環状化合物を含む併用療法
US20180117059A1 (en) Methods for treating egfr mutant cancers
JP2020079243A (ja) ＰＩ３Ｋインヒビターとｃ−Ｍｅｔインヒビターの組み合わせ
EA030808B1 (ru) ПРИМЕНЕНИЕ 1-ЭТИЛ-7-(2-МЕТИЛ-6-(1Н-1,2,4-ТРИАЗОЛ-3-ИЛ)ПИРИДИН-3-ИЛ)-3,4-ДИГИДРОПИРАЗИНО[2,3-b]ПИРАЗИН-2(1Н)-ОНА В ЛЕЧЕНИИ МУЛЬТИФОРМНОЙ ГЛИОБЛАСТОМЫ
JP2019038821A (ja) Ｐｉｍキナーゼ阻害剤の組合せ
KR20140146086A (ko) 티로신 키나제 억제제 조합물 및 그의 용도
US20250032458A1 (en) Treatment of cancer with an fgfr kinase inhibitor
WO2024220421A1 (en) Treatment of cancer with a met kinase inhibitor
US20240269136A1 (en) Egfr inhibitor and perk activator in combination therapy and their use for treating cancer
EP4536648A1 (en) Novel ras inhibitors
JP2022532383A (ja) 増殖状態に対する組み合わせ療法
US20250339387A1 (en) Mitoxanthrone derivatives as ras inhibitors
WO2023242104A1 (en) Diaminoacridine derivatives as inhibitors of ras
EP4536633A1 (en) Novel ras inhibitors
JP2025524343A (ja) 新規ｒａｓ阻害剤
AU2011293315A1 (en) Use of a receptor-type kinase modulator for treating polycystic kidney disease

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20140930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1203 Withdrawal of no request for examination
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid